^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Alemtuzumab is recommended in elderly patients with CLL and del(17p) or TP53 mutation.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL with del(17p)/TP53 mutation...Other recommended regimens...Alemtuzumab ± rituximab
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Excerpt:
    Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...
    DOI:
    10.1182/blood-2003-10-3729